Dean Y Maeda

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 18

Top Topics

Prostate Cancer

Radical Prostatectomy

Top Venues

Science immunology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Saifun Nahar, Yue Huang, Bethany A Nagy, John A Zebala, Dean Y Maeda, Udo Rudloff, Joost J Oppenheim, De Yang
Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. Cancers 15 (8) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Yini Zhu, Yun Zhao, Jiling Wen, Sheng Liu, Tianhe Huang, Ishita Hatial, Xiaoxia Peng, Hawraa Al Janabi, Gang Huang, Jackson Mittlesteadt, Michael Cheng, Atul Bhardwaj, Brandon L Ashfeld, Kenneth R Kao, Dean Y Maeda, Xing Dai, Olaf G Wiest, Brian S J Blagg, Xuemin Lu, Liang Cheng, Jun Wan, Xin Lu
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Science immunology 8 (81) (2023)
Saifun Nahar, Yue Huang, Bethany A Nagy, John A Zebala, Dean Y Maeda, Udo Rudloff, Joost J Oppenheim, De Yang
Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. Cancers 15 (8) (2023)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer 4 (1) (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer 4 (1) (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer 4 (1) (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer 4 (1) (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer (2022)
Pat Gulhati, Aislyn Schalck, Shan Jiang, Xiaoying Shang, Chang-Jiun Wu, Pingping Hou, Sharia Hernandez Ruiz, Luisa Maren Solis Soto, Edwin Roger Parra Cuentes, Haoqiang Ying, Jincheng Han, Prasenjit Dey, Jun Li, Pingna Deng, Emi Sei, Dean Y Maeda, John A Zebala, Denise J Spring, Michael Kim, Huamin Wang, Anirban Maitra, Dirk Moore, Karen Clise-Dwyer, Y Alan Wang, Nicholas E Navin, Ronald A DePinho
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature cancer 4 (1) (2022)
Lucas A Horn, Kristen Fousek, Duane H Hamilton, James W Hodge, John A Zebala, Dean Y Maeda, Jeffrey Schlom, Claudia Palena
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers 13 (5) (2021)
Kwan Ho Tang, Shuai Li, Alireza Khodadadi-Jamayran, Jayu Jen, Han Han, Kayla Guidry, Ting Chen, Yuan Hao, Carmine Fedele, John A Zebala, Dean Y Maeda, James G Christensen, Peter Olson, Argus Athanas, Cynthia A Loomis, Aristotelis Tsirigos, Kwok-Kin Wong, Benjamin G Neel
Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC. Cancer discovery (2021)
Vidya C Sinha, Amanda L Rinkenbaugh, Mingchu Xu, Xinhui Zhou, Xiaomei Zhang, Sabrina Jeter-Jones, Jiansu Shao, Yuan Qi, John A Zebala, Dean Y Maeda, Florencia McAllister, Helen Piwnica-Worms
Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. Nature communications 12 (1) (2021)
Sarah Greene, Yvette Robbins, Wojciech K Mydlarz, Angel P Huynh, Nicole C Schmitt, Jay Friedman, Lucas A Horn, Claudia Palena, Jeffrey Schlom, Dean Y Maeda, John A Zebala, Paul E Clavijo, Clint Allen
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6) (2019)